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haemophilia are classified as <1%, 1 to 5% and >5% to <40%, respectively. 4, 5 Complications of haemophilia, including severe, debilitating chronic joint disease, result in high healthcare resource utilization. 6 Congress passed the Public Health Service Act in 1975 establishing comprehensive haemophilia treatment centres (HTCs) for haemophilia and bleeding disorder care, 3, 7 and in the late 1980s, the Centers for Disease Control and Prevention (CDC) developed and implemented programs intended to ensure blood safety and to reduce complications from bleeding disorders. 8 Public health surveillance is commonly defined as the ongoing, systematic collection, analysis and interpretation of data, along with the dissemination of findings to stakeholders capable of preventing or controlling disease progression. 9 The most comprehensive 100 000 males in 1994. The incidence over the study period was 1 in 5032 live male births. Nearly, four out of five cases had haemophilia A (79%) and 43% of all cases were severe. 6 It was also discovered that HTCs reduce mortality in haemophilia patients by 40% and decrease healthcare resource utilization and cost of care. 10 The 
| MATERIAL S AND ME THODS
The IHSS was an active surveillance system adapted from the methods of the HSS project. The IHSS was a joint collaboration be- The IHSS defined a confirmed haemophilia case as a person with physician-diagnosed factor VIII or factor IX deficiency and a clotting factor activity level of < 50%. A probable case was defined as a person with either a physician diagnosis of factor VIII or factor IX deficiency, a clotting factor activity level of < 50%, or self-reported diagnosis with confirmed clotting factor product dispensation. Severity level was categorized as severe if the activity level was <1%, moderate, if the level was 1%-5%, and mild, if the level was 6%-49%. We excluded persons with a diagnosis of acquired haemo- Patients who had contact with a medical facility during at least one of the surveillance years, either in person or via phone, and met inclusion criteria were eligible for inclusion in IHSS. Mortality rates and causes of death among identified haemophilia cases were assessed based on death certificate data. Death certificates were obtained for patients already identified via other methods and vital statistics were queried for haemophilia listed as a cause of death during the study period.
Prevalence rates were estimated by dividing the number of confirmed and probable cases by the estimated Indiana male population in 2011-2013 and multiplied by 100 000 to express the estimate as the number of cases per 100 000 males. Age-adjusted rates were calculated using US 2010 population estimates. Associations between demographic information and clinical characteristics were assessed for statistical significance using chi-square and Fisher's exact tests.
To estimate incidence, the number of new cases, based on the dates of birth for prevalent cases, within the given year was used as the numerator and the number of live male births in Indiana during the given year was used as the denominator and multiplied by 100 000 to express the rate per 100 000 live male births. The years used to calculate incidence were the 10 years prior to the study period.
| RE SULTS
During the study period, 599, 623, and 634 male cases of haemophilia were identified in 2011, 2012 and 2013, respectively, with a total of 704 unique male cases identified. Those 704 cases formed the study population, of which 662 (94.0%) cases were confirmed, meaning they had both physician and laboratory diagnoses, and 42 (6.0%) cases were probable, having either a physician, laboratory or self-reported diagnosis. Confirmed and probable cases were included in the analysis.
Mean age (±SD) of the study population was 29.7 (±21.0) years, and the median age was 25 years. Figure 1 Nearly, two-thirds of cases (64.8%; 456) had factor VIII deficiency and 35.2% (248 cases) had factor IX deficiency. Among those with known severity levels (685), 233 (34.0%) were severe, 185 (27.0%) moderate, and 267 (39.0%) mild. Nineteen (2.7%) cases had unknown severity levels (Table 1) . Statistical analysis showed a significant association between type of haemophilia and severity (P < 0.0001) and cases identifying as Amish and type of haemophilia (P < 0.0001) and severity (P < 0.0001). Despite representing about 7% of the study population, the Amish population accounted for 17.7% of all factor IX cases. A majority of all our haemophilia cases (85.5%) were non-Hispanic white, 8.5% were non-Hispanic Black, 1.7% were Hispanic, and 2.0% were listed as other races or multiracial. The remaining 2.3% of cases had an undetermined race.
Overall, 575 (81.7%) cases were seen at an HTC at least once during the three-year study period. Of those not seen at an HTC during the study period (129) There were 634 identified cases of haemophilia in 2013. The age-adjusted prevalence of haemophilia in 2013 was 19.4 cases per 100 000 males, 12.7 per 100 000 for factor VIII and 6.7 per 100 000 for factor IX. The mean incidence of haemophilia over the 10 years before the study began (2001-2010) was 30.1 per 100 000 or 1:3688 live male births in Indiana. The average incidence for factor VIII and factor IX patients was 1:5433 and 1:15252, respectively.
Twenty-four patients (3.4%) died during the study period, all but one of whom were adults. The median age of death was 57.5 years, which was younger than median age of death of males in the United States of 79 years. 11 The majority of patients who died (20) were of mild and moderate severity. There was no significant association between mortality and the setting where patients received care; 25% of deaths (n = 6) occurred in cases outside of the HTC network. 
| D ISCUSS I ON
We report the first assessment of the prevalence and incidence of haemophilia within Indiana. The average incidence of haemophilia during the study period was roughly 1:3700 live male births, which is higher than the generally accepted frequency of haemophilia of roughly 1 in 5000 live male births. The estimated haemophilia prevalence in Indiana was 45% higher than previously reported in the United States. 6 Figure 1 Early mortality for many patients exposed to HIV and hepatitis from plasma-derived blood products in the early 1980s greatly contributed to decreased prevalence of haemophilia in the older strata.
The largest percentage of patients in our study were in an age range (15-24 years) that had little to no exposure to contaminated blood products. Figure 2 and more than 75 fold larger than Oklahoma and Colorado (<600, <350, respectively). 12 This report is thus the largest known surveillance of haemophilia prevalence among an Amish population.
Disease severity has implications for the care required to prevent and limit haemophilia-related complications. In our cohort, 
| Limitations
This study has limitations. First, the clinical data for patients seen outside of the HTC setting were less complete than for patients seen at HTCs. The missing data could result in underestimation of the occurrence of certain clinical characteristics. In addition, lack of participation from several physicians and clinics may have resulted in a failure to identify some patients not captured by the administrative data sets and hospital discharge data. Finally, probable patients (n = 42) were included in the analysis, which may have led to a slight overestimation of prevalence. These patients are likely true haemophilia patients but not all criteria for confirmation were met.
Exclusion of these cases would not appreciably affect estimated prevalence. 
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